All In Biotech

Investigational drug · Phase 3

Savolitinib

Also called: hmpl-504, AZD6094

Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

11

8 still active

All registered trials

48

Any phase or sponsor naming "Savolitinib"

First trial start

2017

Jul 25, 2017

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Savolitinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Carcinoma
  • Non-small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Urologic Neoplasms
  • Kidney Diseases
  • Neoplasms by Site
  • Enzyme Inhibitors
  • Protein Kinase Inhibitors

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Savolitinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 192 on PubMed

Also in development for Carcinoma

  • STAR0602InvikafuspPhase 22 trials

    Marengo Therapeutics, Inc. · Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumors

  • KVA12123Phase 21 trial

    Kineta Inc. · Cancer, Solid Tumor, Melanoma

  • NRC-2694-APhase 21 trial

    NATCO Pharma Ltd. · Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

  • ST-067Phase 21 trial

    Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.